The JAK inhibitor field is beginning to heat up – AbbVie is soon to enter Phase 3 with its predicted best-in-class therapy, Gilead is working with Galapagos on a potential rival and Celgene started the year off with a $1.1 billion upfront deal for Impact Biomedicine, gaining them access to its JAK2 inhibitor.
Theravance seals potential $1bn deal with J&J
